(Q38024835)

27 August 2017

title

Novel actions of progesterone: what we know today and what will be the scenario in the future? (English)

1 reference

27 August 2017

1 reference

Shilpa N Kaore

1

1 reference

27 August 2017

Deepak Kumar Langade

2

1 reference

27 August 2017

Vijay Kumar Yadav

3

1 reference

27 August 2017

Parag Sharma

4

1 reference

27 August 2017

Vijay R Thawani

5

1 reference

27 August 2017

Raj Sharma

6

1 reference

27 August 2017

language of work or name

1 reference

21 February 2012

1 reference

Journal of Pharmacy and Pharmacology

27 August 2017

published in

1 reference

27 August 2017

volume

64

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

1040-1062

1 reference

Modulation of traumatic brain injury using progesterone and the role of glial cells on its neuroprotective actions

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone in the clinical treatment of acute traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone as a neuroprotective factor in traumatic and ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone as a neurosteroid: actions within the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Ovarian hormones, aging and stress on hippocampal synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Mechanisms of progesterone-induced neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone-induced neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroactive steroids: state of the art and new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Pharmacology of endogenous neuroactive steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The sticky issue of neurosteroids and GABA(A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroids: endogenous regulators of the GABA(A) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Dihydroprogesterone increases the gene expression of myelin basic protein in spinal cord of diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone and the spinal cord: good friends in bad times

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone neuroprotection in spinal cord trauma involves up-regulation of brain-derived neurotrophic factor in motoneurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Megestrol acetate: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of progesterone on male-mediated infant-directed aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroactive steroids and peripheral myelin proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Hippocampal neurons in pre-clinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Serum steroids in relation to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Converse regulatory functions of estrogen receptor-alpha and -beta subtypes expressed in hypothalamic gonadotropin-releasing hormone neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Sex steroid hormone metabolism and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The role of 5alpha-reduction in steroid hormone physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Isolation of 24-epibrassinolide from leaves of Aegle marmelos and evaluation of its antigenotoxicity employing Allium cepa chromosomal aberration assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of 24-epibrassinolide on growth and metal uptake in Brassica juncea L. under copper metal stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Steroid 5alpha-reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Synthesis and biological activity of progesterone derivatives as 5alpha-reductase inhibitors, and their effect on hamster prostate weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

New 5alpha-reductase inhibitors: in vitro and in vivo effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Androgen, estrogen, and progesterone receptors in normal and aging prostates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone and maternal aggressive behavior in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone receptors mediate male aggression toward infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The progesterone receptor and parental behavior in juvenile rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Paternal care in rodents: weakening support for hormonal regulation of the transition to behavioral fatherhood in rodent animal models of biparental care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of hormonal contraception on bone mineral density after 24 months of use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progestogen-only contraception and bone mineral density: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Bone growth and turnover in progesterone receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Pre-eclampsia-like conditions produced by nitric oxide inhibition: effects of L-arginine, D-arginine and steroid hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Prenatal progesterone II. Its role in the treatment of pre-eclamptic toxaemia and its effect on the off-spring's intelligence: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Prediction and primary prevention of pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Sex differences in the contribution of nicotine and nonpharmacological stimuli to nicotine self-administration in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: persisting effects on locomotor activity, learning and nicotine self-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Cigarette smoking by women: interactions with alcohol use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of menstrual phase and smoking abstinence in smokers with and without a history of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Sex and ovarian hormones influence vulnerability and motivation for nicotine during adolescence in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Menstrual phase effects on smoking relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Menstrual cycle phase effects on nicotine withdrawal and cigarette craving: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Drug insight: Recent advances in male hormonal contraception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Male hormonal contraceptives: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Endocrine approaches to male fertility control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Sex, sex steroids, and brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Absence of evidence for the effectiveness of five interventions routinely used in the intensive care management of severe head injury: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Gender influences outcome of brain injury: progesterone plays a protective role

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Brain damage, sex hormones and recovery: a new role for progesterone and estrogen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone protects against lipid peroxidation following traumatic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Protection from traumatic brain injury in hormonally active women vs men of a similar age: a retrospective international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Long-term global and regional brain volume changes following severe traumatic brain injury: a longitudinal study with clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Combination therapies for traumatic brain injury: prospective considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Sex differences in brain damage and recovery of function: experimental and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone in traumatic brain injury: time to move on to phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone exerts neuroprotective effects after brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The membrane-associated progesterone-binding protein 25-Dx: expression, cellular localization and up-regulation after brain and spinal cord injuries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone receptors: form and function in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone potentiates calcium release through IP3 receptors by an Akt-mediated mechanism in hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone increases brain-derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone, BDNF and neuroprotection in the injured CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone for the treatment of experimental brain injury; a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Does progesterone have neuroprotective properties?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroids: beginning of the story

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone: therapeutic opportunities for neuroprotection and myelin repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progestin receptor-mediated reduction of anxiety-like behavior in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Effects of progesterone and testosterone on ICH-induced brain injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroprotective effects of progesterone following stroke in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone suppresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Treatment with progesterone after focal cerebral ischemia suppresses proliferation of progenitor cells but enhances survival of newborn neurons in adult male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone exacerbates striatal stroke injury in progesterone-deficient female animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Sustained levels of progesterone prior to the onset of cerebral ischemia are not beneficial to female mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone and allopregnanolone attenuate blood–brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase-->AKT-->GSK-3beta-->cyclin D1-->pRB pathway to block uterine epithelial cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

3 Beta-hydroxysteroid dehydrogenase expression in rat spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Recent developments in the significance and therapeutic relevance of neuroactive steroids--Introduction to the special issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroid regulation of central nervous system development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroids: biosynthesis and function of these novel neuromodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

The neurosteroids pregnenolone and pregnenolone-sulfate but not progesterone, block Ca2+ currents in acutely isolated hippocampal CA1 neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Behavior and physiology of mice lacking the GABAA-receptor delta subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroprotective actions of brain aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroid biosynthesis in the human brain and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroprogesterone: key to estrogen positive feedback?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Regenerative potential of allopregnanolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroactive steroids and peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Carpal tunnel syndrome: pathophysiology and clinical neurophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Progesterone prevents nerve injury-induced allodynia and spinal NMDA receptor upregulation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Therapeutic approaches to peripheral neuropathy based on neuroactive steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neurosteroids: measurement and pathophysiologic relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Liver X receptors regulate adrenal cholesterol balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.2012.01464.X

10.1111/J.2042-7158.2012.01464.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference